Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab plus Fludarabine in Relapsed/Refractory B-CLL
NCT00206726Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2005
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Sanofi. Primary endpoint: Complete Response. Started May 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00206726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206726.